Novel Strategies to Enhance Vaccine Immunity against Coccidioidomycosis

1. FisherFS, BultmanMW, JohnsonSM, PappagianisD, ZaborskyE (2007) Coccidioides niches and habitat parameters in the southwestern United States: a matter of scale. Ann N Y Acad Sci 1111 : 47–72.

2. BlundellGP, CastleberryMW, LoweEP, ConverseJL (1961) The pathology of Coccidioides immitis in the Macaca mulatta. Am J Pathol 39 : 613–630.

3. WiseHZ, HungCY, WhistonE, TaylorJW, ColeGT (2013) Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. Microb Pathog 59–60 : 19–28.

4. Anonymous (2013) Increase in reported coccidioidomycosis -⁠ United States, 1998–2011. Morb Mortal Wkly Rep 62 : 217–221.

5. Marsden-HaugN, GoldoftM, RalstonC, LimayeAP, ChuaJ, et al. (2013) Coccidioidomycosis acquired in Washington State. Clin Infect Dis 56 : 847–850.

6. RuddyBE, MayerAP, KOMG, LabonteHR, BorovanskyJA, et al. (2011) Coccidioidomycosis in African Americans. Mayo Clin Proc 86 : 63–69.

7. ColeGT, HurtgenBJ, HungC-Y (2012) Progress toward a human vaccine against coccidioidomycosis. Curr Fungal Infect Rep 6 : 235–244.

8. PappagianisD (1993) Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Study Group. Am Rev Respir Dis 148 : 656–660.

9. XueJ, ChenX, SelbyD, Hung-Y, YuJ-J, ColeGT (2009) A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77 : 3196–3208.

10. BalamayooranT, BatraS, BalamayooranG, CaiS, KobayashiKS, et al. (2011) Receptor-interacting protein 2 controls pulmonary host defense to Escherichia coli infection via the regulation of interleukin-17A. Infect Immun 79 : 4588–4599.

11. HungC-Y, GonzalezA, WüthrichM, KleinBS, ColeGT (2011) Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17). Infect Immun 79 : 4511–4522.

12. HungC-Y, HurtgenBJ, BellecourtM, SandersonSD, MorganEL, et al. (2012) An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine 30 : 4681–4690.

13. MorganEL, MorganBN, SteinEA, VitrsEL, ThomanML, et al. (2009) Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 28 : 463–469.

14. PhillipsJA, MorganEL, DongY, ColeGT, McMahanC, et al. (2009) Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjug Chem 20 : 1950–1957.

15. FiererJ, WatersC, WallsL (2006) Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J Infect Dis 193 : 1323–1331.

16. NanjappaSG, HeningerE, WüthrichM, GasperDJ, KleinBS (2012) Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 8: e1002771 doi:10.1371/journal.ppat.1002771

17. HurtgenBJ, HungC-Y, OstroffGR, LevitzSM, ColeGT (2012) Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect Immun 80 : 3960–3974.

18. RosaDS, RibeiroSP, Cunha-NetoE (2010) CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp (Warsz) 58 : 121–130.

19. HuangH, OstroffGR, LeeCK, SpechtCA, LevitzSM (2010) Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. MBio 1: e00164–10.

20. IkeuchiN, FutamiJ, HosoiA, NojiS, KurachiM, et al. (2010) Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun 392 : 217–222.

21. TeszGJ, AouadiM, ProtM, NicoloroSM, BoutetE, et al. (2011) Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 436 : 351–362.

22. TamerisMD, HatherillM, LandryBS, ScribaTJ, SnowdenMA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial. Lancet 381 : 1021–1028.

23. RappuoliR, MandlCW, BlackS, De GregorioE (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11 : 865–872.

24. MorganEL, ThomanML, SandersonSD, PhillipsJA (2010) A novel adjuvant for vaccine development in the aged. Vaccine 28 : 8275–8279.

25. LivingstonB, CrimiC, NewmanM, HigashimotoY, AppellaE, et al. (2002) A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168 : 5499–5506.

26. YanoA, OnozukaA, Asahi-OzakiY, ImaiS, HanadaN, et al. (2005) An ingenious design for peptide vaccines. Vaccine 23 : 2322–2326.